SlideShare ist ein Scribd-Unternehmen logo

Aiden hollis hif presentation berkeley

•Als PPT, PDF herunterladen•
•
O
Open Science Summit
1 von 18
A New Way of Stimulating Research & Development for Life-Saving Pharmaceuticals July 31 , 2010 AIDAN HOLLIS [email_address]
Outline ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The problems ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
An open science proposal ,[object Object],[object Object],[object Object],[object Object]
Scylla and Charybdis ,[object Object],[object Object],[object Object],[object Object]
Open Science meets Scylla and Charybdis ,[object Object],[object Object],[object Object],[object Object],[object Object]
Clinical trials ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The Health Impact Fund ,[object Object],[object Object],[object Object],[object Object],[object Object]
Proposed Reward Mechanism ,[object Object],[object Object],[object Object],[object Object],[object Object]
Why would innovators opt in? ,[object Object],[object Object],[object Object],[object Object],[object Object]
Health Impact Assessment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Financing ,[object Object],[object Object],[object Object],[object Object]
The HIF Resolves Three Critical Problems in Prize Determination ,[object Object],[object Object],[object Object],[object Object],[object Object]
The HIF and open science ,[object Object],[object Object],[object Object],[object Object]
Next Step: A Pilot ,[object Object],[object Object],[object Object],[object Object],[object Object]
Outcomes of the Pilot ,[object Object],[object Object],[object Object],[object Object]
Developing the proposal ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Thank you! ,[object Object],[object Object]

Empfohlen

BioEntrepreneurship: Life Science Business Models
BioEntrepreneurship: Life Science Business ModelsBioEntrepreneurship: Life Science Business Models
BioEntrepreneurship: Life Science Business ModelsMaRS Discovery District
 
BioEntrepreneurship: The Business of Biotech
BioEntrepreneurship: The Business of BiotechBioEntrepreneurship: The Business of Biotech
BioEntrepreneurship: The Business of BiotechMaRS Discovery District
 
Business Plan on a Bio-Tech product
Business Plan on a Bio-Tech productBusiness Plan on a Bio-Tech product
Business Plan on a Bio-Tech productTarkeshwar Singh
 
Pharmaceutical Porter analysis
Pharmaceutical Porter analysisPharmaceutical Porter analysis
Pharmaceutical Porter analysisPharm Net
 
Future Pharma Trends - Long-term opportunities tempered by short-term challenges
Future Pharma Trends - Long-term opportunities tempered by short-term challengesFuture Pharma Trends - Long-term opportunities tempered by short-term challenges
Future Pharma Trends - Long-term opportunities tempered by short-term challengesscottosur
 
Generic Medicine and its Future Prospects in India
Generic Medicine and its Future Prospects in India Generic Medicine and its Future Prospects in India
Generic Medicine and its Future Prospects in IndiaAnkita Bharti
 
Regenerative Medicine Industry Outlook 2014
Regenerative Medicine Industry Outlook 2014Regenerative Medicine Industry Outlook 2014
Regenerative Medicine Industry Outlook 2014Pete Shuster
 
2017 Case Workshop III - Breakout Session A
2017 Case Workshop III - Breakout Session A2017 Case Workshop III - Breakout Session A
2017 Case Workshop III - Breakout Session AConsulting Club at the Texas Medical Center
 

Empfohlen

BioEntrepreneurship: Life Science Business Models
BioEntrepreneurship: Life Science Business ModelsBioEntrepreneurship: Life Science Business Models
BioEntrepreneurship: Life Science Business ModelsMaRS Discovery District
 
BioEntrepreneurship: The Business of Biotech
BioEntrepreneurship: The Business of BiotechBioEntrepreneurship: The Business of Biotech
BioEntrepreneurship: The Business of BiotechMaRS Discovery District
 
Business Plan on a Bio-Tech product
Business Plan on a Bio-Tech productBusiness Plan on a Bio-Tech product
Business Plan on a Bio-Tech productTarkeshwar Singh
 
Pharmaceutical Porter analysis
Pharmaceutical Porter analysisPharmaceutical Porter analysis
Pharmaceutical Porter analysisPharm Net
 
Future Pharma Trends - Long-term opportunities tempered by short-term challenges
Future Pharma Trends - Long-term opportunities tempered by short-term challengesFuture Pharma Trends - Long-term opportunities tempered by short-term challenges
Future Pharma Trends - Long-term opportunities tempered by short-term challengesscottosur
 
Generic Medicine and its Future Prospects in India
Generic Medicine and its Future Prospects in India Generic Medicine and its Future Prospects in India
Generic Medicine and its Future Prospects in IndiaAnkita Bharti
 
Regenerative Medicine Industry Outlook 2014
Regenerative Medicine Industry Outlook 2014Regenerative Medicine Industry Outlook 2014
Regenerative Medicine Industry Outlook 2014Pete Shuster
 
2017 Case Workshop III - Breakout Session A
2017 Case Workshop III - Breakout Session A2017 Case Workshop III - Breakout Session A
2017 Case Workshop III - Breakout Session AConsulting Club at the Texas Medical Center
 
Merck: Global Health and Access to Medicines
Merck: Global Health and Access to MedicinesMerck: Global Health and Access to Medicines
Merck: Global Health and Access to MedicinesTony Sebastian
 
Global regenerative medicines market (technology, application and geography) ...
Global regenerative medicines market (technology, application and geography) ...Global regenerative medicines market (technology, application and geography) ...
Global regenerative medicines market (technology, application and geography) ...Allied Market Research
 
2017 Case Workshop III - Breakout Session B
2017 Case Workshop III - Breakout Session B2017 Case Workshop III - Breakout Session B
2017 Case Workshop III - Breakout Session BConsulting Club at the Texas Medical Center
 
Roadmap to reimbursement and access
Roadmap to reimbursement and accessRoadmap to reimbursement and access
Roadmap to reimbursement and accessRhonda Greenapple
 
Early asset development and commercialization: Partnering for success
Early asset development and commercialization: Partnering for successEarly asset development and commercialization: Partnering for success
Early asset development and commercialization: Partnering for successCello Health
 
Presentation_Mark_Tsunami - 1505
Presentation_Mark_Tsunami - 1505Presentation_Mark_Tsunami - 1505
Presentation_Mark_Tsunami - 1505Gulf Healthcare
 
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?BioEntrepreneurship: Intellectual Property: What Do Investors Look For?
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?MaRS Discovery District
 
PAN_Celgene in China
PAN_Celgene in ChinaPAN_Celgene in China
PAN_Celgene in ChinaTamra Sami
 
Genentech
GenentechGenentech
GenentechMarianna Malaspina
 
Market access the challenges for medical devices
Market access the challenges for medical devices Market access the challenges for medical devices
Market access the challenges for medical devices Amy Morgan
 
Is European market access becoming an incubator for rare disease development?...
Is European market access becoming an incubator for rare disease development?...Is European market access becoming an incubator for rare disease development?...
Is European market access becoming an incubator for rare disease development?...KateBenson18
 
Case study on merck
Case study on merckCase study on merck
Case study on merckEshaan Chhagotra
 
Market access medical devices-white paper
Market access medical devices-white paperMarket access medical devices-white paper
Market access medical devices-white paperDr. Kavita Lamror
 
From Research to Revenue IV: Capturing Business Opportunities in Asia
From Research to Revenue IV: Capturing Business Opportunities in AsiaFrom Research to Revenue IV: Capturing Business Opportunities in Asia
From Research to Revenue IV: Capturing Business Opportunities in AsiaGHBN
 
Healthcare
HealthcareHealthcare
HealthcareKasmhir Fae Salvador
 
Hetero Europe company presentation 2010
Hetero Europe company presentation 2010Hetero Europe company presentation 2010
Hetero Europe company presentation 2010Generic Pharma 2.0
 
Regenerative medicine scotland v2
Regenerative medicine scotland v2Regenerative medicine scotland v2
Regenerative medicine scotland v2Regenerative_Medicine
 
Wharton Undergraduate Healthcare Conference- Merck Revenue Growth Plan
Wharton Undergraduate Healthcare Conference- Merck Revenue Growth PlanWharton Undergraduate Healthcare Conference- Merck Revenue Growth Plan
Wharton Undergraduate Healthcare Conference- Merck Revenue Growth PlanKazim Ali
 
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...Mercer Capital
 
Advancing Medicine, Improving Lives. Presentation.
Advancing Medicine, Improving Lives. Presentation.Advancing Medicine, Improving Lives. Presentation.
Advancing Medicine, Improving Lives. Presentation.ALIKAUSAR58
 
Pink army july 31
Pink army july 31Pink army july 31
Pink army july 31Open Science Summit
 
Hirsch open science
Hirsch open scienceHirsch open science
Hirsch open scienceOpen Science Summit
 

Weitere ähnliche Inhalte

Was ist angesagt?

Merck: Global Health and Access to Medicines
Merck: Global Health and Access to MedicinesMerck: Global Health and Access to Medicines
Merck: Global Health and Access to MedicinesTony Sebastian
 
Global regenerative medicines market (technology, application and geography) ...
Global regenerative medicines market (technology, application and geography) ...Global regenerative medicines market (technology, application and geography) ...
Global regenerative medicines market (technology, application and geography) ...Allied Market Research
 
Roadmap to reimbursement and access
Roadmap to reimbursement and accessRoadmap to reimbursement and access
Roadmap to reimbursement and accessRhonda Greenapple
 
Early asset development and commercialization: Partnering for success
Early asset development and commercialization: Partnering for successEarly asset development and commercialization: Partnering for success
Early asset development and commercialization: Partnering for successCello Health
 
Presentation_Mark_Tsunami - 1505
Presentation_Mark_Tsunami - 1505Presentation_Mark_Tsunami - 1505
Presentation_Mark_Tsunami - 1505Gulf Healthcare
 
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?BioEntrepreneurship: Intellectual Property: What Do Investors Look For?
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?MaRS Discovery District
 
PAN_Celgene in China
PAN_Celgene in ChinaPAN_Celgene in China
PAN_Celgene in ChinaTamra Sami
 
Market access the challenges for medical devices
Market access the challenges for medical devices Market access the challenges for medical devices
Market access the challenges for medical devices Amy Morgan
 
Is European market access becoming an incubator for rare disease development?...
Is European market access becoming an incubator for rare disease development?...Is European market access becoming an incubator for rare disease development?...
Is European market access becoming an incubator for rare disease development?...KateBenson18
 
Market access medical devices-white paper
Market access medical devices-white paperMarket access medical devices-white paper
Market access medical devices-white paperDr. Kavita Lamror
 
From Research to Revenue IV: Capturing Business Opportunities in Asia
From Research to Revenue IV: Capturing Business Opportunities in AsiaFrom Research to Revenue IV: Capturing Business Opportunities in Asia
From Research to Revenue IV: Capturing Business Opportunities in AsiaGHBN
 
Hetero Europe company presentation 2010
Hetero Europe company presentation 2010Hetero Europe company presentation 2010
Hetero Europe company presentation 2010Generic Pharma 2.0
 
Wharton Undergraduate Healthcare Conference- Merck Revenue Growth Plan
Wharton Undergraduate Healthcare Conference- Merck Revenue Growth PlanWharton Undergraduate Healthcare Conference- Merck Revenue Growth Plan
Wharton Undergraduate Healthcare Conference- Merck Revenue Growth PlanKazim Ali
 
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...Mercer Capital
 
Advancing Medicine, Improving Lives. Presentation.
Advancing Medicine, Improving Lives. Presentation.Advancing Medicine, Improving Lives. Presentation.
Advancing Medicine, Improving Lives. Presentation.ALIKAUSAR58
 

Was ist angesagt? (20)

Merck: Global Health and Access to Medicines
Merck: Global Health and Access to MedicinesMerck: Global Health and Access to Medicines
Merck: Global Health and Access to Medicines
 
Global regenerative medicines market (technology, application and geography) ...
Global regenerative medicines market (technology, application and geography) ...Global regenerative medicines market (technology, application and geography) ...
Global regenerative medicines market (technology, application and geography) ...
 
2017 Case Workshop III - Breakout Session B
2017 Case Workshop III - Breakout Session B2017 Case Workshop III - Breakout Session B
2017 Case Workshop III - Breakout Session B
 
Roadmap to reimbursement and access
Roadmap to reimbursement and accessRoadmap to reimbursement and access
Roadmap to reimbursement and access
 
Early asset development and commercialization: Partnering for success
Early asset development and commercialization: Partnering for successEarly asset development and commercialization: Partnering for success
Early asset development and commercialization: Partnering for success
 
Presentation_Mark_Tsunami - 1505
Presentation_Mark_Tsunami - 1505Presentation_Mark_Tsunami - 1505
Presentation_Mark_Tsunami - 1505
 
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?BioEntrepreneurship: Intellectual Property: What Do Investors Look For?
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?
 
PAN_Celgene in China
PAN_Celgene in ChinaPAN_Celgene in China
PAN_Celgene in China
 
Genentech
GenentechGenentech
Genentech
 
Market access the challenges for medical devices
Market access the challenges for medical devices Market access the challenges for medical devices
Market access the challenges for medical devices
 
Is European market access becoming an incubator for rare disease development?...
Is European market access becoming an incubator for rare disease development?...Is European market access becoming an incubator for rare disease development?...
Is European market access becoming an incubator for rare disease development?...
 
Case study on merck
Case study on merckCase study on merck
Case study on merck
 
Market access medical devices-white paper
Market access medical devices-white paperMarket access medical devices-white paper
Market access medical devices-white paper
 
From Research to Revenue IV: Capturing Business Opportunities in Asia
From Research to Revenue IV: Capturing Business Opportunities in AsiaFrom Research to Revenue IV: Capturing Business Opportunities in Asia
From Research to Revenue IV: Capturing Business Opportunities in Asia
 
Healthcare
HealthcareHealthcare
Healthcare
 
Hetero Europe company presentation 2010
Hetero Europe company presentation 2010Hetero Europe company presentation 2010
Hetero Europe company presentation 2010
 
Regenerative medicine scotland v2
Regenerative medicine scotland v2Regenerative medicine scotland v2
Regenerative medicine scotland v2
 
Wharton Undergraduate Healthcare Conference- Merck Revenue Growth Plan
Wharton Undergraduate Healthcare Conference- Merck Revenue Growth PlanWharton Undergraduate Healthcare Conference- Merck Revenue Growth Plan
Wharton Undergraduate Healthcare Conference- Merck Revenue Growth Plan
 
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...
 
Advancing Medicine, Improving Lives. Presentation.
Advancing Medicine, Improving Lives. Presentation.Advancing Medicine, Improving Lives. Presentation.
Advancing Medicine, Improving Lives. Presentation.
 

Andere mochten auch

Choque Cultural - Brasil X Alemanha - por Leonardo Sarmento Leonardo
Choque Cultural - Brasil X Alemanha - por Leonardo Sarmento Leonardo Choque Cultural - Brasil X Alemanha - por Leonardo Sarmento Leonardo
Choque Cultural - Brasil X Alemanha - por Leonardo Sarmento Leonardo reporteroo
 

Andere mochten auch (8)

Pink army july 31
Pink army july 31Pink army july 31
Pink army july 31
 
Hirsch open science
Hirsch open scienceHirsch open science
Hirsch open science
 
Delinkage oss2010 jameslove_kei
Delinkage oss2010 jameslove_keiDelinkage oss2010 jameslove_kei
Delinkage oss2010 jameslove_kei
 
Choque Cultural - Brasil X Alemanha - por Leonardo Sarmento Leonardo
Choque Cultural - Brasil X Alemanha - por Leonardo Sarmento Leonardo Choque Cultural - Brasil X Alemanha - por Leonardo Sarmento Leonardo
Choque Cultural - Brasil X Alemanha - por Leonardo Sarmento Leonardo
 
Ready2Bake
Ready2BakeReady2Bake
Ready2Bake
 
Oss2010 sci flies
Oss2010 sci fliesOss2010 sci flies
Oss2010 sci flies
 
5 s antes
5 s antes5 s antes
5 s antes
 
Koepsell who owns you
Koepsell who owns youKoepsell who owns you
Koepsell who owns you
 

Ähnlich wie Aiden hollis hif presentation berkeley

WHAT IF: A health impact fund rewarded innovation and managed spending on new...
WHAT IF: A health impact fund rewarded innovation and managed spending on new...WHAT IF: A health impact fund rewarded innovation and managed spending on new...
WHAT IF: A health impact fund rewarded innovation and managed spending on new...CFHI-FCASS
 
The Role of clinical Research in Pharmaceuticals Industry
The Role of clinical Research in Pharmaceuticals IndustryThe Role of clinical Research in Pharmaceuticals Industry
The Role of clinical Research in Pharmaceuticals IndustryVarsha Chauhan
 
Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history EstelaJeffery653
 
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...Nejmeddine Jemaa
 
Accelerating Generic Approvals by Dr Anthony Crasto
Accelerating Generic Approvals by Dr Anthony CrastoAccelerating Generic Approvals by Dr Anthony Crasto
Accelerating Generic Approvals by Dr Anthony CrastoAnthony Melvin Crasto Ph.D
 
Changing the Medical Research Paradigm
Changing the Medical Research ParadigmChanging the Medical Research Paradigm
Changing the Medical Research ParadigmRAWE_INC
 
Cost on development of new drug
Cost on development of new drugCost on development of new drug
Cost on development of new drugDrAsimraza
 
Commercial considerations in early drug development
Commercial considerations in early drug developmentCommercial considerations in early drug development
Commercial considerations in early drug developmentSunil Ramkali
 
What's In An Idea-Chanda-UofT Life Science Coach
What's In An Idea-Chanda-UofT Life Science CoachWhat's In An Idea-Chanda-UofT Life Science Coach
What's In An Idea-Chanda-UofT Life Science CoachDebra A. Chanda
 
Ethical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesEthical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesKuldeep Badoniya
 
orphan drugs writeup.doc
orphan drugs writeup.docorphan drugs writeup.doc
orphan drugs writeup.docsuprajakotam
 
The Orphan Drug Act
The Orphan Drug ActThe Orphan Drug Act
The Orphan Drug Actbiotechpro
 
Globalization Of Clinical Trials 2010 Josep M. Badenas
Globalization Of Clinical Trials 2010 Josep M. BadenasGlobalization Of Clinical Trials 2010 Josep M. Badenas
Globalization Of Clinical Trials 2010 Josep M. Badenasjosepmariabadenas
 
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREADPinky Fadullon
 
Clinical Recruitment Planning Strategies
Clinical Recruitment Planning StrategiesClinical Recruitment Planning Strategies
Clinical Recruitment Planning StrategiesMFinch3777
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug ReportBill Smith
 
mHealth Israel_Michael Breman_Nov 2014
mHealth Israel_Michael Breman_Nov 2014mHealth Israel_Michael Breman_Nov 2014
mHealth Israel_Michael Breman_Nov 2014Michal Faktor
 

Ähnlich wie Aiden hollis hif presentation berkeley (20)

WHAT IF: A health impact fund rewarded innovation and managed spending on new...
WHAT IF: A health impact fund rewarded innovation and managed spending on new...WHAT IF: A health impact fund rewarded innovation and managed spending on new...
WHAT IF: A health impact fund rewarded innovation and managed spending on new...
 
The Role of clinical Research in Pharmaceuticals Industry
The Role of clinical Research in Pharmaceuticals IndustryThe Role of clinical Research in Pharmaceuticals Industry
The Role of clinical Research in Pharmaceuticals Industry
 
Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history
 
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...
 
Accelerating Generic Approvals by Dr Anthony Crasto
Accelerating Generic Approvals by Dr Anthony CrastoAccelerating Generic Approvals by Dr Anthony Crasto
Accelerating Generic Approvals by Dr Anthony Crasto
 
Changing the Medical Research Paradigm
Changing the Medical Research ParadigmChanging the Medical Research Paradigm
Changing the Medical Research Paradigm
 
Beyond borders
Beyond bordersBeyond borders
Beyond borders
 
Reimaging pharmaceutical innovation
Reimaging pharmaceutical innovationReimaging pharmaceutical innovation
Reimaging pharmaceutical innovation
 
Cost on development of new drug
Cost on development of new drugCost on development of new drug
Cost on development of new drug
 
Commercial considerations in early drug development
Commercial considerations in early drug developmentCommercial considerations in early drug development
Commercial considerations in early drug development
 
What's In An Idea-Chanda-UofT Life Science Coach
What's In An Idea-Chanda-UofT Life Science CoachWhat's In An Idea-Chanda-UofT Life Science Coach
What's In An Idea-Chanda-UofT Life Science Coach
 
Ethical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesEthical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research Incentives
 
orphan drugs writeup.doc
orphan drugs writeup.docorphan drugs writeup.doc
orphan drugs writeup.doc
 
The Orphan Drug Act
The Orphan Drug ActThe Orphan Drug Act
The Orphan Drug Act
 
Globalization Of Clinical Trials 2010 Josep M. Badenas
Globalization Of Clinical Trials 2010 Josep M. BadenasGlobalization Of Clinical Trials 2010 Josep M. Badenas
Globalization Of Clinical Trials 2010 Josep M. Badenas
 
Emerging Strategies in Drug Innovation
Emerging Strategies in Drug InnovationEmerging Strategies in Drug Innovation
Emerging Strategies in Drug Innovation
 
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
 
Clinical Recruitment Planning Strategies
Clinical Recruitment Planning StrategiesClinical Recruitment Planning Strategies
Clinical Recruitment Planning Strategies
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug Report
 
mHealth Israel_Michael Breman_Nov 2014
mHealth Israel_Michael Breman_Nov 2014mHealth Israel_Michael Breman_Nov 2014
mHealth Israel_Michael Breman_Nov 2014
 

Mehr von Open Science Summit

David ewing duncan open science 7-30-10
David ewing duncan open science 7-30-10David ewing duncan open science 7-30-10
David ewing duncan open science 7-30-10Open Science Summit
 
Barry bunin open science summit at the berkeley intl house 2010
Barry bunin open science summit at the berkeley intl house 2010Barry bunin open science summit at the berkeley intl house 2010
Barry bunin open science summit at the berkeley intl house 2010Open Science Summit
 
Myelin repair open science summit 07.31.10 v2
Myelin repair open science summit 07.31.10 v2Myelin repair open science summit 07.31.10 v2
Myelin repair open science summit 07.31.10 v2Open Science Summit
 
Cordeiro education2030berkeleyopensciencesummit2010
Cordeiro education2030berkeleyopensciencesummit2010Cordeiro education2030berkeleyopensciencesummit2010
Cordeiro education2030berkeleyopensciencesummit2010Open Science Summit
 
Carol mimura open society july 31, 2010, copy
Carol mimura open society july 31, 2010, copyCarol mimura open society july 31, 2010, copy
Carol mimura open society july 31, 2010, copyOpen Science Summit
 
Keith oss 2010 - ip-based platforms
Keith oss 2010 - ip-based platformsKeith oss 2010 - ip-based platforms
Keith oss 2010 - ip-based platformsOpen Science Summit
 
Vitrant fund science opensciencesummit2010presentation
Vitrant fund science opensciencesummit2010presentationVitrant fund science opensciencesummit2010presentation
Vitrant fund science opensciencesummit2010presentationOpen Science Summit
 
Fbi open science summit presentation (29 july 2010)
Fbi open science summit presentation (29 july 2010)Fbi open science summit presentation (29 july 2010)
Fbi open science summit presentation (29 july 2010)Open Science Summit
 
Open science darwinian method pictures 2 (vasser)
Open science darwinian method pictures 2 (vasser)Open science darwinian method pictures 2 (vasser)
Open science darwinian method pictures 2 (vasser)Open Science Summit
 

Mehr von Open Science Summit (20)

David ewing duncan open science 7-30-10
David ewing duncan open science 7-30-10David ewing duncan open science 7-30-10
David ewing duncan open science 7-30-10
 
Izant openscience
Izant openscienceIzant openscience
Izant openscience
 
Barry bunin open science summit at the berkeley intl house 2010
Barry bunin open science summit at the berkeley intl house 2010Barry bunin open science summit at the berkeley intl house 2010
Barry bunin open science summit at the berkeley intl house 2010
 
Batten oss 727 -bw changes
Batten oss 727 -bw changesBatten oss 727 -bw changes
Batten oss 727 -bw changes
 
Myelin repair open science summit 07.31.10 v2
Myelin repair open science summit 07.31.10 v2Myelin repair open science summit 07.31.10 v2
Myelin repair open science summit 07.31.10 v2
 
Beth baber oen science summit
Beth baber oen science summitBeth baber oen science summit
Beth baber oen science summit
 
Cordeiro education2030berkeleyopensciencesummit2010
Cordeiro education2030berkeleyopensciencesummit2010Cordeiro education2030berkeleyopensciencesummit2010
Cordeiro education2030berkeleyopensciencesummit2010
 
Rebecca goulding alt ip
Rebecca goulding alt ipRebecca goulding alt ip
Rebecca goulding alt ip
 
Lisa green oss deck
Lisa green oss deckLisa green oss deck
Lisa green oss deck
 
Carol mimura open society july 31, 2010, copy
Carol mimura open society july 31, 2010, copyCarol mimura open society july 31, 2010, copy
Carol mimura open society july 31, 2010, copy
 
Keith oss 2010 - ip-based platforms
Keith oss 2010 - ip-based platformsKeith oss 2010 - ip-based platforms
Keith oss 2010 - ip-based platforms
 
Bennett open access_7-31-10
Bennett open access_7-31-10Bennett open access_7-31-10
Bennett open access_7-31-10
 
4 cowell oss-07302010
4 cowell oss-073020104 cowell oss-07302010
4 cowell oss-07302010
 
1 reinhoff berkeley july 2010
1 reinhoff berkeley july 20101 reinhoff berkeley july 2010
1 reinhoff berkeley july 2010
 
Vitrant fund science opensciencesummit2010presentation
Vitrant fund science opensciencesummit2010presentationVitrant fund science opensciencesummit2010presentation
Vitrant fund science opensciencesummit2010presentation
 
Fbi open science summit presentation (29 july 2010)
Fbi open science summit presentation (29 july 2010)Fbi open science summit presentation (29 july 2010)
Fbi open science summit presentation (29 july 2010)
 
2010 opensciencepeterson
2010 opensciencepeterson2010 opensciencepeterson
2010 opensciencepeterson
 
Open science darwinian method pictures 2 (vasser)
Open science darwinian method pictures 2 (vasser)Open science darwinian method pictures 2 (vasser)
Open science darwinian method pictures 2 (vasser)
 
Nielsen
NielsenNielsen
Nielsen
 
Lqts oss 30_july20102010
Lqts oss 30_july20102010Lqts oss 30_july20102010
Lqts oss 30_july20102010
 

Aiden hollis hif presentation berkeley

  • 1. A New Way of Stimulating Research & Development for Life-Saving Pharmaceuticals July 31 , 2010 AIDAN HOLLIS [email_address]
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.

Hinweis der Redaktion

  1. Thanks to Joseph for inviting me
  2. Bernard Munos
  3. Unpatentable drugs – eg nearing the end of patent life – get no investmetn in clinical trials, unlike younger drugs.